Related Experiment Video

Updated: May 13, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Myeloma and thrombotic complications

I Tzoran1, B Brenner, R Hoffman

  • 1Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus, Haifa, Israel.

Minerva Medica
|March 22, 2013
PubMed

Insights

Multiple myeloma patients face a high risk of thrombosis, including arterial events. This review details risk factors, prevention strategies, and treatments for thrombosis in multiple myeloma.

Area of Science:

  • Hematology
  • Oncology
  • Vascular Medicine

Background:

  • Multiple myeloma (MM) is a hematological cancer associated with a significant risk of thrombosis.
  • While venous thromboembolism is more frequent, arterial thrombosis also occurs in MM patients.
  • Thrombotic complications in MM arise from patient-specific, disease-related, and treatment-induced factors.

Purpose of the Study:

  • To review the multifaceted risk factors contributing to thrombosis in multiple myeloma.
  • To outline current recommendations for thromboprophylaxis in MM patients.
  • To discuss therapeutic strategies for managing thrombosis within the context of MM treatment.

Main Methods:

  • Literature review of studies on thrombosis in multiple myeloma.
  • Analysis of risk factors, including patient, myeloma, and treatment-related elements.
  • Synthesis of evidence regarding thromboprophylaxis and treatment guidelines.

Main Results:

  • Identified patient-related factors (e.g., age, comorbidities) influencing thrombosis risk.
  • Highlighted myeloma-specific factors (e.g., disease activity, specific mutations) impacting thrombotic events.
  • Detailed treatment-related risks (e.g., certain chemotherapies, immunomodulatory drugs) and their association with thrombosis.

Conclusions:

  • Thrombosis is a critical complication in multiple myeloma requiring vigilant management.
  • Risk stratification and tailored thromboprophylaxis are essential for MM patients.
  • Integrated strategies addressing patient, disease, and treatment factors are necessary for optimal outcomes.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...